Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
ICD-10 D83.1 is a billable code used to indicate a diagnosis of common variable immunodeficiency with predominant immunoregulatory t-cell disorders.
Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder characterized by low levels of serum immunoglobulins and an increased susceptibility to infections. In patients with predominant immunoregulatory T-cell disorders, there is a dysfunction in T-cell regulation, leading to an imbalance in immune responses. This can result in autoimmune manifestations, lymphoproliferative disorders, and an increased risk of malignancies. Clinically, patients may present with recurrent bacterial infections, particularly of the respiratory and gastrointestinal tracts, as well as chronic diarrhea and autoimmune conditions such as autoimmune hemolytic anemia or thrombocytopenia. Diagnosis is typically made through serological testing showing low immunoglobulin levels and the exclusion of other causes of hypogammaglobulinemia. Management often involves immunoglobulin replacement therapy and treatment of infections and autoimmune complications. Regular monitoring is essential to manage the risk of complications associated with this condition.
Detailed immunological assessments, including immunoglobulin levels and T-cell function tests.
Patients presenting with recurrent infections, autoimmune disorders, or lymphoproliferative diseases.
Ensure comprehensive documentation of all clinical manifestations and treatments to support coding.
Complete blood counts, reticulocyte counts, and documentation of any hematologic complications.
Patients with autoimmune hemolytic anemia or thrombocytopenia secondary to CVID.
Document any transfusions or treatments related to hematologic conditions.
Used for patients receiving immunoglobulin therapy for CVID.
Document the indication for therapy and patient response.
Immunology specialists should ensure that the therapy is linked to the diagnosis.
The primary treatment for CVID is immunoglobulin replacement therapy, which helps to prevent infections and manage autoimmune complications.
